A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel with or without RAD001 in Patients with Triple-negative Locally Advanced Breast Cancer (SPORE)

Trial Profile

A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel with or without RAD001 in Patients with Triple-negative Locally Advanced Breast Cancer (SPORE)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Everolimus (Primary) ; Cisplatin; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms SPORE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Mar 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 06 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top